clinical trial · NCT06817356
A Study to Evaluate Mazdutide Compared With Placebo in Participants With Alcohol Use Disorder
Eli Lilly and Company·phase2·active not recruiting·n = 300
Alcohol Use DisorderMazdutidePlacebo
brief summary
The objective of this proof-of-concept study to evaluate mazdutide in participants with alcohol use disorder (AUD). For any individual participant, the maximum duration of study participation is approximately 36 weeks, including screening and posttreatment follow-up.
started
Feb 6, 2025
primary completion
Aug 1, 2026
completion
Aug 1, 2026
last updated
Mar 27, 2026
official title
A Phase 2, Double-Blind, Proof of Concept Study to Evaluate Mazdutide Compared With Placebo in Participants With Alcohol Use Disorder
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol